Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HB-0025 by Huabo Biopharm (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Non-Small Cell Lung Cancer. According...
HB-0025 by Huabo Biopharm (Shanghai) for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Squamous Non-Small Cell Lung Cancer....
HB-0025 by Huabo Biopharm (Shanghai) for Renal Cell Carcinoma: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Renal Cell Carcinoma. According to...
HB-0025 by Huabo Biopharm (Shanghai) for Endometrial Cancer: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Endometrial Cancer. According to GlobalData,...
HB-0025 by Huabo Biopharm (Shanghai) for Hepatocellular Carcinoma: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...